Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-24-091250
Filing Date
2024-10-28
Accepted
2024-10-28 17:03:29
Documents
16
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K ea0218384-10ka1_estrella.htm   iXBRL 10-K/A 301812
2 CERTIFICATION ea021838401ex31-3_estrella.htm EX-31.3 3371
3 CERTIFICATION ea021838401ex31-4_estrella.htm EX-31.4 3329
  Complete submission text file 0001213900-24-091250.txt   603638

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE esla-20240630.xsd EX-101.SCH 3675
5 XBRL DEFINITION FILE esla-20240630_def.xml EX-101.DEF 19544
6 XBRL LABEL FILE esla-20240630_lab.xml EX-101.LAB 39467
7 XBRL PRESENTATION FILE esla-20240630_pre.xml EX-101.PRE 20346
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0218384-10ka1_estrella_htm.xml XML 8915
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 0630
Type: 10-K/A | Act: 34 | File No.: 001-40608 | Film No.: 241401672
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)